Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aligos Therapeutics (Nasdaq: ALGS), a clinical stage biopharmaceutical company specializing in liver and viral diseases, has announced an inducement grant under Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Summary

Aligos Therapeutics (Nasdaq: ALGS), a clinical stage biopharmaceutical company specializing in liver and viral diseases, has announced an inducement grant under Nasdaq Listing Rule 5635(c)(4). The company's Compensation Committee approved a non-qualified stock option to purchase 4,000 shares for a newly hired employee on March 11, 2025.

The grant, issued through Aligos' 2024 Inducement Plan, serves as an employment inducement and has an exercise price matching the closing price of Aligos' common stock on the grant date. The shares will vest over four years, with 25% vesting after the first year and the remaining portion vesting in equal monthly installments, contingent on continued employment.

Argus Session date unavailable

+11.28% session move Open Argus

Details

News Market Reaction – ALGS

The recorded move for ALGS in the trading session of this news was +11.28%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted a non-qualified stock option to purchase an aggregate of 4,000 shares of the Company’s stock (the “Inducement Grant”) to a newly hired employee on March 11, 2025 (the “Grant Date”), in connection with the commencement of employment.

The Inducement Grant was granted pursuant to Aligos’ 2024 Inducement Plan (the “Plan”) as an inducement material to this individual entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Aligos.

The Inducement Grant has an exercise price per share equal to the closing price of Aligos’ common stock on the Grant Date. The shares subject to the Inducement Grant will vest over a four-year period, with 25% vesting on the first anniversary of the Grant Date and the remainder vesting in equal monthly installments, subject to the continued employment through the applicable vesting dates.

About Aligos

Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics with high unmet medical needs such as chronic hepatitis B virus infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses.

For more information, please visit www.aligos.com or follow us on LinkedIn or X.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Such forward-looking statements are subject to substantial risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical stage of development, the process of designing and conducting clinical trials and the regulatory approval processes. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 10, 2025 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

Aligos Therapeutics

Contact
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
+1 (650) 910-0427
jtarazi@aligos.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What are the vesting terms for Aligos Therapeutics' (ALGS) March 2025 inducement grant?

The shares vest over 4 years - 25% after year one, with remaining shares vesting monthly, subject to continued employment.

How many shares were included in Aligos Therapeutics' (ALGS) March 2025 inducement grant?

The inducement grant includes options to purchase 4,000 shares of company stock.

What is the exercise price for ALGS's March 2025 inducement grant?

The exercise price equals Aligos' common stock closing price on March 11, 2025 (the Grant Date).

When was the ALGS inducement grant approved and under what regulation?

The grant was approved on March 11, 2025, under Nasdaq Listing Rule 5635(c)(4) through Aligos' 2024 Inducement Plan.